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A major goal of signal transduction research is to identify 
the substrates and roles of the many protein kinases. 
The task might be simplified by the discovery that the 
mutation of a single amino acid dramatically alters the 
nucleotide specificity of protein kinases and their 
inhibition by a particular class of anti-inflammatory drug. 
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‘l-he reversible phosphorylation of proGns. catalvscd 11) 
protein kinascs and protein phosphatases. regulates most 
aspects of ccl1 life, including the control of gcnc transcrip- 
tion, cell growth and differentiation, the control of metabo- 
lism and secretion. the immune response, fertilisation, and 
cvcn the acquisition of memory. l‘he pt”)sphor);lation of 
prowins at scrinc, threoninc and tyrosinc residues alters 
their shape, and hence their ability to function. but it can 
also affect other parameters, such as the rate at which pro- 
teins arc degraded and the ability of the prorcins to miptc 
from one cellular location to another. ‘I’hc simplicity. flcxi- 
bilit); and re\.ersibilit)- of protein ~~hosl~hor);lation probably 
explains why this co\Aent modification has been adopted 
by cukatyotic cells as their principal control mechanism. 
One of the long-term goals of signal transduction research 
is to identify the intracellular substratcs and the physio- 
logical roles of each protein kinasc and protein phos- 
phatasc. but this is a major challcngc because about one 
third of all mammalian proteins, some 30.000 proteins. 
contain coAcntly bound phosphate. Mnreovcr. the 
human gcnome encodes 1000-2000 protein kinascs (the 
largest single gene family) and 300-.X0 protein phos- 
phatases. ‘i’hus. the ‘awrage protein kinasc phosphor);- 
law 1.5-30 substraws and the ‘average’ protein 
phosphatase dcphosphor~lates 50-100 intracellular pro- 
teins. ‘I’hc problem is ma& wcn harder by the tremen- 
dous redundancy and overlapping substrate specificities of 
many protein kinases. 
‘I‘hc development of new and impro\:cd merhods for idcn- 
tifying the intraccllulat substrates of protein kinaccs and 
phosphatascs is critical. IIcre. WC rc\:ic\v two indcpcndcnt 
lines of investigation that recently introduced no\:el 
approaches that might be hclpf111 in tackling this problem. 
One approach invol\;es engineering protcin kinascs with 
altcrcd nuclcotidc speciticitics, whetcas the other ctcaces 
protcin kineses that arc sensitive to inhibition by a partic- 
ular class of anti-inflammatory drug. Remarkably. both 
approaches are based on miitagcncsis of the same amino 
acid in the kinase catalytic domain. 
Engineering protein kinases with novel nucleotide 
specificities 
In 1997, Ke\.an Shokat and his colleagues [ 1 ] embarked on 
a strategy aimed ar changing the nuclcoticie specificities 01 
protein kinascs. Their go& was to product a mutant 
protein kinasc with two key properties. Firstly. the kinase 
had to bc able to accept with high catalytic efficient) an 
Sh-substituted ATP rhat the wild-type enzyme (or any 
other intracellular protein kinasc) would not acccpc. Sec- 
ondly, the mutant kinasc had to USC ATP with a lower cat- 
alytic cfficicnc! than the wild-t>pe enzyme. so that the 
V-substituted ~Yl‘f’ woi~ld be llsed prcfcrcntiall\i. If this 
colild tx achieved, it mighr bc possible to identify the 
substrates of a protein kinasc simply by introducing the 
mutant protein kinasc and the “‘I’-labclled .X6-substituted 
:\TP into cell Iyates or intact cells. because the substrates 
of other protein kinascs should not bc radiolabcllcd under 
these conditions [ 11. 
Inspection of the A’I’P-binding pockets of cyclic .\Rll’- 
dcpcndcnt protein kinase (I’KA) and c~clin-dcpcndent 
protein kinasc 2 (cdk2) rcvcalcd that only two amino acid 
sidechains \vcre within a .5 A sphcrc of the X0 amino 
group of the bound :I17 (Figure la). Shokat and col- 
Icagues [l] thcrcfote mutatcd tht: equivalent residues 
(\‘a1323 and Tlc.338) in the oncogcnic protein rytosine 
kinasc I:-Src to alaninc, the rationale being that a much 
smaller sidcchain might cteatc an additional ‘pocket’ in 
the nuclcotidc-l)illcin:: site that would allow patticlllar 
h”-substituted ATP cieri\lativcs m intcracc with the 
mutant, but not the wild-type. enzyme. These studies led 
to rhc discovery that the \‘323A/LMSA double mutant 
(but not the wild-rypc v-Src) was able 10 ritilisc 
X6-(cyclopentyl) ATP (I:igure 1 b) as a substraw. Jlore- 
over. no protein hccame ph0sphor) latcd when ;I Iympho- 
cytc extract \vas incubated with x6-(cyclopcnr);l) ;\TP. 
implying that no other cellular protein kinasc ~a$ able to 
urilise this X6-substituted :\‘I?. ‘I’hc \~.123-\/1338:\ 
double muwnt also had a lower affinity for ATI’ than did 
the wild-type v-Stc [I]. 
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MAP kinase family member Sequence surrounding ThrlOG ’ 
SAPK2alp38 SNI~~LVTHLMGI~Il; 
SAPK2b/p38\32 1, SEVYi.VTTLXADL 
SAPK3fp30y :-':DFYLVMPFMGTDI, 
SAPK4lp386 'YCFYLVMPF‘KQT >L 
SAPKly/JNKl FQ3Y:~VMfX:OANI, ’ 
SAPKl P/JNK2/3 F()DVY;VMZf.XD.W. 
MAPKPIERKP ;~:KI)~~IVQl)iI~~Tl:L 




Type II TGFB receptor GKr;sr;i'ilTkFffAKG~ , 
Type I TGFB receptor ~;~73L~~~LVSDYf-:~EGS 
Some protein kinases with a bulky hydrophobic residue 
at the position equivalent to ThrlO6 
I 
Protein kmase A NSNLYWMEWPGGF: 
Protein kinase C VIl3LYI''JMEY'v'XGGI? 
CaM-dependent protein kinase II EGHfIYLlFDLVTGCS 
Cyclin-dependent kinase 2 
1 
ENKi>YLVF3:.3QD; 
Glycogen synthase kinase-3cx X,YLNI,VLSYVPC'I'V 
-.-. - - - ..- c-ms:ry 8% ?Iclogy -. 
Amino acid sequences surrounding the residue equivalent to the 
threonme in SAPK2a/p38 and SAPK2b/p38j32 that confers sensitivity 
to SB 203580. Residues in the position equivalent to Thr106 in 
SAPK2a/p38 are shown in bold. 
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Structures of (a) ATP, (b) N6-(cyclopentyl) ATP and (c) N6-(benzyl) ATP. 
‘I’he gcncration of a V-SW rnlltant with a novel nucleocidc 
specificit! (but with a similar suhstratc specificity) was 
encouraging, but the k,z,I/K,n \:alue of the mIltant with 
W(cyclopcnt);l) A’l’f’ was still .50-fold lower than chat of 
the wild-type cnz):mc with ATI’ [ 11. This led to the starch 
for an ‘improved’ miltant and, in a recent issiJc of L?ietn&q 
&?Bio/oD, Shokat and co\vorkers [Z] ha1.e achieved this feat. 
They show that the key rcsidJJe in engineering a nol:el 
nucleotidc specificity is 11~338 (l;igure 2, shown in bold in 
v&c), and find that KCQenz);l) ATP (Figure lc) is a 
better slJbstrate for 133&A or 1338G v-Cc than 
S6-(qclopentyl) ATP. ‘I’he k,,,/K, of 133% I:-Src lvith 
S6-(bcnzyl) ,!‘l’I’ as a substratc is only fourfold lower than 
that of wild-type v-Src with .ATP. The catalytic domain of 
the Fyn tyrosine kinase is 85% identical to that of Src. 
Ylutdtion of rhe eqiJivalent residoc. Thr339. in 1:)-n to 
glycinc (Figure 2) produced a JnJJtant whose k_,/K,,, with 
x6-(benql) XTP was just as high as chat of wild-type F);n 
with ATP [Z]. :\s expected. No-(benzyl) A’I’P and 
N6-(c~clopcntyl)A’I’I were potent inhibitors of the ATP- 
dependent activic); of 13386 v-Src or ‘r339(; Fyi, but did 
JJot inhibit wild-type v-Src or wild-tyc Fyn 121. 
In silmmar):, the prcscnce of a bulky residue at position 
338 of v-Src or position 339 of Fyi prcvcnts these Src 
family mcmhers from utilising V-substituted ATP deriv- 
ati\:es. The ability to produce miltant protein kinascs that 
utilise N”-(cpclopcntyl) LITI’ and S”-(benzyl) A’I’P dcriv- 
atives potentially forms rhc basis of a method for ‘tagging’ 
the phgsiological sJJbstrates of these protein kinases in the 
presence of ever); ocher cellular protein kinase. 
Engineering a specific cell-permeable inhibitor of mutant 
13386 v-Src that does not affect wild-type v-Src 
In a ftlrcher rcccnt paper [3], Shokat and colleagues have 
extended these studies b\: identifying a cell-pcrmeablc 
inhibitor of I338(; v-Src that does not inhibit wild-type 
\:-Src. This !vas achieved by making deriva&:es of ;I pya- 
Lolol3.4~dlpyrirnidinc (Figure 3a) known to be an 
inhibitor of Src family members. It was reasoned that this 
compolJnd was likely to bind in a similar manner to 
quercctin, an inhibitor of many protcin kinascs lvhosc 
interaction with the Src Family member Hck has been 
solved by X-ray crystallography [4]. In this case, the S4 
position of pyrazolo[3.4-n]p);rimidinc corresponds to the 
A’” position of ATP and a panel of Nj-subsGtutcd ana- 
logucs were therefore synthesised. One of these. the 
NJ(p-ter/-but~lphen~l) derivaCvc (I:igurc 3b) was found 
to inhibit I338G v&c (IC5,, = 430 nX:l) or T339G Fyn 
(ICs, = 830 n1.l) without inhibiting the wild-type 
cnzymcs, even at .500-1000-fold higher concentrations 
than those required to inhibit the mlJtants. Interestingly, 
this compound (unlike the llnmoditicd p~razolo[3,-I- 
c/jpyrimidine compound) did not affect tyrosine phos- 
phorylarion induced by cross-linking the R-cell receptor, 
establishing that the deri\;ative dots not inhibit any of the 
intracellular protein t):rosinc kinascs that lit on this sig- 
nailing path\\;‘)‘. Excitingly. the S4(1’-l”l-but).lptien):I) 
derilativc suppressed both the phosphorvlation of 1’36 (a 
putative v-Src substrate) and cell transformation induced 
by expression of 1338G v-Src. In contrast, p36 phosphor):- 
lation and cell transformation induced b); w-ild-t)pe v-Src 
were unaffected [ 31. 
Basis for the specificity of the anti-inflammatory drug 
SB 203580 
.A class of pyridin):l imidazoles was identified by John 
I,ee and his colleagues at SmithKlinc Bcccham [S] that 
suppresses the svnthcsis (and some of the actions) of pro- 
inflammatory c):tokincs and that shows promise for the 
treatment of rheumatoid arthritis and other chronic 
inflammatory conditions [6]. 0ne of these compounds is 
SB 203.580 (T;igurc 3~). Lvhich has been shown to be a 
rcmarkablr specific inhibitor of stress-activated protein 
(SAP) kinasc 2a (SL\I’K2a. also called ~38) and SAP 
kinase-Zb (S.WKZb. also called p38p2) [5,7,81. SR 203580 
has been used to identify some of the physiological 
substraccs and cellular functions of S.APKZa/p.% and 
SAPK2b/p38~2 (reviewed in [F)]). 
SAPKZa/p.% and S:\PK2b/p.%QZ. which show 74% amino 
acid sequcncc identity, arc mcmbcrs of the mitogcn-acti- 
vatcd protcin (Al.4P) kinasc family. S,WK3/p38y and 
SAI’K4jp386 arc Tao other mcmbcrs of the same protein 
family. with 60% sequence identity to ShPK2a/piX and 
SAPK2b/p.%$2. IYnlike Sr\PKZa/p.X and SAPK2h/p3XP2. 
howcvcr? SAI’K3/p38y and SAI’K4/p386 arc not inhibited 
by- S13 203580 [8], thus raisin, (7 the question of the mccha- 
nism underlying the specificity of this p):ridin)l imidazole 
compound. SB 203580 binds to its protcin kinasc targets 
compctitivcly with XTP [ 101 and elllcidation of the three- 
dimensional structure of SXf’KZa/p38 in complex with 
closely related pyridinyl imidazoles has established that 
thcsc drugs arc inscrtcd into the A’I’P-binding pocket of 
S;\PK2a/p38 [ 11,121. The 4-fluoropheql ring of the drug 
does not make contact with residues that interact with 
A’I‘I’. hou;c\:cr. 0nc rcsiduc near the 4-fluorophcnyl ring is 
ThrlO6. which is conscr\,cd in SAPK2b/p38P2 but is 
replaced 1)~ methionine in SWK3/p3Xy and SXI’K4/p386 
(Figure 2). ‘I’his suggcstcd that the rcsistancc of these 
protein kinases to SR 203580 might bc cxplaincd b); the 
presence of a large sidcchain at this position, and two recent 
mutagenesis studies have rcvcalcd that this is indeed the 
cast il3,141. Thus, SAPK3/p38y and ShI’Kl/p386 become 
sensitive to SU 203.580, when the methionine is changed 
to thrconinc whcrcas. converseIF, S1\PK2a/p38 and 
SAI’KZb/p38~2 become resistant to the drug when ‘I’hrlOh 
is changed to mcthionine 113.14J. I;llrther mutagcncsis 




(a) Inhibitor of wild-type v-Src 
(b) Inhibitor of 1338G v-Src and T339G Fyn 
(c) Inhibitor of wild-type SAPK2a/p38 and SAPK2b/p38P2 
Chcmfstry & B ology 
Structures of (a) pyrazolo[3,4-djpyrlmidine. (b) the N4(p-terCbutylpheny1) 
derivative of pyrazolo[3.4-dpyrlmidine and Cc) the pyridinyl lmldazole 
inhibitor SB 203580. 
rcvcalcd that S:\PK3/p38y lxco~nes more scnsiti1.c to the 
drug ( ICjo = 1 O-.50 nJl) \chen the mcthionine is rcplaccd 
1~~ cl;cn smaller residues. such as serine, alanine or glycine. 
SXPK2a/p38, S.-\I’KZb/p38~2 and SXl’K4/p386 also become 
most senciti1.e to SH 203580 (I(:io = 15-30 n\l). when 
glycinc or alaninc is prcscnt at this position [13]. In addition 
to ThrlO6 of SIIPK2a/p38, HislO’ and I,eu108 also con- 
tribute to the sensiti\+): of SAPK2a/p38 towards SB 203580 
[14]. ‘I’hese residues are proline and phen~lalanine in 
SAI’K3/p3Sy and SAI’K4/p386. \\‘hcn the rcsiducs arc 
replaced I)): histidine and leucine. \I 1OOT S.\PK3/pNyand 
\1107T SAPK4/pXF become more sensitive to inhibition 
by SI3 203580 [ 141. 
SAJ’Kl/JSK. another h~IAl’ kinasc family mcmhcr. is 
only 40% identical to SAPK2a/p.78 and S.APK2b/p.V#2. 
Nevertheless. SAPKl/JSK can also IX convcrtcd to ;_I 
Sl3 203580-sensitive form by mutation of AIct108 
(Figure 2) to a small amino acid. ‘1‘0 optimise sensiti\.it) 
to the drug. however. it was also ncccssar): to change 
IlclOG to the lcrlcinc rcsiduc prcscnt at the equi\-alent 
position in other .\l:\l’ kinase family members. The 
I lOhl./\~I 108A double mutant was inhibited with an ICZi, 
value of 30 n\;l 1131. ;\llOX in S:WKl/JNK is follo\ved by 
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glutamate. ~1108’1’/KlOOII SAPKl/JI\‘K is inhibited by S13 
203580 with an Its,, value of 1 p\l, as comprcd to an IC:,i, 
value of lOl.~hl for f~I108T SAI’Kl/JNK 1141. It will be 
interesting to study the inhibition of I1001,/~1108A/ElO~I1 
SXPKl/JSK by S13 203.580. 
Most known marnmalian protein kinases halle a large, 
hydrophobic residue at the position equivalent to ThrlOO 
of SAPKZa/p%j (Figure 2). \,‘cry few protein kinascs have 
thrconinc at this position and only one (the type I TGFp 
rcccptor) has scrinc (Figllrc 2). So known protcin kinase 
has glycinc or alaninc at this position. ‘I‘wo protein kinascs 
with threoninc at this position, the type II ‘I’GFP receptor 
and the tyrosinc protein kinase I,ck (Figllrc 2), were 
shown to be sensitive to inhibition by SR 203.580. 
although the IC,,, values were 400-800 times higher than 
the lCj, value for SAPKZa/p.M. Scverthclcss, sensitivity 
of the t):pc II ‘I’GFP rcccptor to SH 203.580 \vas abolished 
by mutagenesis to methioninc. but enhanced by mutagen- 
csis to alaninc. ‘I-he type I TC;F;P rcccptor was inhil-nted 
slightly more potently b): SB 203.580, consistent with the 
prcscnce of the smaller serinc r&due at this position [ 1.11. 
In summary. the size of the residue at the position equiw- 
Icnt to ‘l’hr106 of SAPK2a/p38 is critical and diagnostic for 
dctcrmining \shcthcr a protein kinase will bc sensitive to 
SB 203.580. It will be intcrcsting to XC how many of the 
rcportcd effects of SD 203.580 in mammalian cells are abol- 
ished by transfection with a drug-insensitive form of 
SAf’KZa/p38. It will also bc interesting to see lvhcthcr 
SR 203.580 can bc used to study the physiological roles of 
other protein kinascs by replacin, (r the drllg-insensitive 
wild-type enzymes with SH 203580-sensiti\:c mutants. 
Conclusions 
ThrlO6 of SAPK2a/p38 and IL338 of \:-Src arc cclui\alcnt 
residues in the kinasc catalytic domain. It is remarkable 
that two indepcndcnt lines of rcscarch have identified this 
single amino acid as being critical for the ability to accept 
N%ubstituted ATP derivatives. as well as for the scnsitiv- 
it): to inhibition by the anti-inflammatory drug SB 203.580. 
For a protein kinasc to bc sensitive to SH 203580. the 
sidcchain of this residue must be no larger than that of 
threonine, the scnsitivit): being enhanced when the size of 
the sidcchain is wcn smaller. ‘I’hc high dcgrcc of speci- 
ficity of SR 203.580 is explained by the presence of a large 
sidechain at this position in nearly all known protein 
kinases. For a protein kinasc to accept S”-(c):clopcntyl) 
ATP or N”-(benzyl) .A’I’P, I lowcvcr, the sidcchain must be 
glycine or alanine. Intriguingly. no protein kinasc in the 
public databases has glycine or alanine at this position. 
which presumably explains why no protein kinases have 
been derectcd in cell Iysatcs that are capable of utilising 
X6-(cyclopent):l) ATP or \“-(bcnzyl) A’I‘I’. As stable cell 
lines expressing a mutant protein kinasc and even ‘knock- 
in’ mice can bc generated quite rapidly, the replaccmcnt 
of a wild-t!;pc protein kinase I,): a mutant enzyme that has 
accliiircd a novel nucleotidc specificity or scnsiti\+ty to a 
particular drug offers a new approach for identifying the 
physiological substrates and roles of protein kinases. It 
remains to be seen how useful this approach v.ill turn out 
to bc. but thcrc is more than a glimmer of hope that it will 
















Shah, K., LIU. Y.. Deirmengian, C. & Shokat, K.M. (1997). Engtneenng 
unnatural nucleotlde speclflclty for Rous sarcoma virus tyrosine klnase 
to uniquely label its direct substrates. Proc. Nat/ Acad. SC;. USA 94. 
3565-3570. 
Liu, Y., Shah. K.. Yang, F., Witucki, L. & Shokat. K.M. (1998). 
Engineering Src family protein kinases with unnatural nucleotlde 
speclflclty. Chem. B/o/. 5, 91-101. 
Bishop, A.C., Shah, K., Liu, Y., Wituckl, L., Kung, C.-Y. & Shokat. K.M. 
(1998). Design of allele-specific inhibitors to probe protein klnase 
signaling. Curr. B/o/. 8. 257-266. 
Sicheri, F.. Moarefi, I. & Kuriyan, J. (1997). Crystal structure of the Src- 
family tyrosine kinase Hck. Nature 385, 602-609. 
Lee, J.C., et al.. & Young, P.R. (1994). A protein kinase involved In the 
regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746. 
Badger, A.M.. Bradbeer, J.N., Votta. B.. Lee, J.C.. Adams, J.L. & 
Griswold, D.E. (1996). Pharmacological profile of SB 203580, a 
selective inhibitor of cytokine suppressive binding protein/p38 kinase, 
in anlmal models of arthritis.. bone resorption, endotoxin shock and 
immune function. J. fharmacol. Exp. Ther. 279, 1453-l 461. 
Cuenda, A., et a/., & Lee, J.C. (1995). SB 203580 is a specific 
inhibitor of a MAP kinase homologue which is stimulated by cellular 
stresses and interleukin-1. Ff5.S Left. 364, 229-231. 
Goedert. M.. Cuenda. A., Craxton, M.. Jakes, R. & Cohen. P. (I 997). 
Activation of the novel stress-activated protein kinase SAPK4 by 
cytoklnes and cellular stresses IS mediated by SKK3 (MKKG); 
comparison of its substrate speclflclty with that of other SAP klnases. 
EMBO 1. 16, 3563-357 1. 
Cohen. P. (1997) The search for physiological substrates of MAP and 
SAP kinases In mammalian cells. Trends Cell B/o/. 7. 353-361. 
Young. P.R., et al, & Lee. J.C. (1997). Pyndlnyl imidazole Inhibitors of 
p38 mitogen-acbvated protein kinase bind In the ATP site. J. EGO/. 
Chem. 272, 12116-12121. 
Tong, L., ef al.. & Pargellis, C.A. (1997). A highly specific inhibitor of 
human p38 MAP kinase binds In the ATP pocket. Nat. Struci. Biol. 4, 
31 I-316. 
Wllson, K.P., et al.. & Su. M.S.S. (1997). The structural basis for the 
specificity of pyndlnylimidazole inhibitors of p38 MAP kinase. Chem. 
B/o/. 4, 423-431. 
Eyers, P.A., Craxton. M.. Morrice. N., Cohen. P. & Goedert, M. (1998). 
ConversIon of SB 203580-InsensitIve MAP kinase family members to 
drug-sensitive forms by a single amino acid substltutlon: Chem. Biol. 
5, 321-328. 
Gum, R.J., et a/., &Young. P.R. (1998). Acquisition of sensitivity of 
stress-activated protein kinases to the p38 InhIbItor, SB 203580, by 
alteratlon of one or more amino acids within the ATP binding pocket. 
J. B/o/. Chem., in press. 
